Ivo Christian Lorenz

20100215691, Aug 26, 2010

Feb 19, 2010

12/708940

Christopher L. PARKS - Boonton NJ, US
Ivo Lorenz - Brooklyn NY, US
Sanjay K. Phogat - Frederick MD, US
Timothy J. Zamb - Nyack NY, US

A61K 39/12
C12N 15/63
C12N 7/08
A61P 31/18

4241991, 4353201, 435237

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

20130129778, May 23, 2013

Oct 26, 2012

13/661737

International AIDS Vaccine Initiative - New York NY, US
Micheal J. Caulfield - Fort Washington PA, US
Ivo C. Lorenz - Brooklyn NY, US
Christopher L. Parks - Boonton NJ, US

International AIDS Vaccine Initiative - New York NY

A61K 39/21

4241991

The invention relates to generating a vaccine based on immunogens from viral particles that initially have replication competency but are then inactivated by chemical, biophysical or other methods. The components of this vaccine may be a non-HIV enveloped virus that contains and expresses a gene related to the HIV Envelope gene such that the Envelope protein is expressed on the surface of viral particles. These viral particles may be further treated to reduce their replication competency. The vaccine further may contain components to improve its immunogenicity, tolerability, stability and ease of manufacture.

20130266989, Oct 10, 2013

Mar 10, 2013

13/792103

Christopher L. Parks - Boonton NJ, US
Kevin J. Wright - Brooklyn NY, US
Maoli Yuan - Brooklyn NY, US
Christy K. Jurgens - Rahway NJ, US
Xinsheng Zhang - Merrick NY, US
Arban Domi - Parsippany NJ, US
Simon Hoffenberg - Hartsdale NY, US
Maria J. Chiuchiolo - Brooklyn NY, US
Svetlana Rabinovich - Staten Island NY, US
Aaron J. Wilson - Brooklyn NY, US
Ivo C. Lorenz - Brooklyn NY, US

International AIDS Vaccine Initiative - New York NY

C12N 15/68

435 9141

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.

20090233266, Sep 17, 2009

Mar 9, 2006

11/817782

Charles Rice - New York NY, US
Joseph Marcotrigiano - New Brunswick NJ, US
Ivo C. Lorenz - Brooklyn NY, US

The Rockefeller University - New York NY

C12Q 1/70
C07K 1/00

435 5, 530402

The present invention provides a crystallized C-terminal domain of an NS2 protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the C-terminal domain of hepatitis C virus NS2 protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same.

20220348648, Nov 3, 2022

Jul 8, 2020

17/622404

- New York NY, US
Jason LEWIS - New York NY, US
Abdul KHAN - New York NY, US
David ANDREW - New York NY, US
Xinlei CHEN - New York NY, US
Ivo LORENZ - New York NY, US

C07K 16/28
C12N 15/63
A61P 35/00

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.

20220220222, Jul 14, 2022

Dec 23, 2021

17/561415

- New York NY, US
Isabel Kurth - New York NY, US
Shugaku Takeda - Queens Village NY, US
Ivo Lorenz - Brooklyn NY, US

Inspirna, Inc. - New York NY

C07K 16/40
A61K 47/65
A61K 47/68
A61P 35/00
A61K 39/395

The present disclosure provides antibodies (e.g., humanized antibodies) that specifically bind to Mer Tyrosine Kinase (MERTK; e.g., human MERTK) and compositions comprising such antibodies. The present disclosure also provides antibody-drug conjugates comprising (i) an anti-MERTK antibody or antigen-binding fragment thereof described herein that specifically binds to MERTK (e.g., human MERTK), and (ii) cytotoxic agents conjugated directly to the antibodies or conjugated to the antibodies via linkers, and compositions comprising such antibody-drug conjugates. The present disclosure also provides methods for treating cancer, comprising administering to a human subject in need thereof (a) an anti-MERTK antibody that specifically binds to MERTK (e.g., human MERTK) or an antigen-binding fragment thereof described herein, or (b) an antibody-drug conjugate that comprises (i) an anti-MERTK antibody or antigen-binding fragment thereof that specifically binds to MERTK (e.g., human MERTK), and (ii) a cytotoxic agent conjugated directly to the antibody or conjugated to the antibody via a linker.

20210380696, Dec 9, 2021

May 24, 2021

17/328050

- Ingelheim am Rhein, DE
Nicole K. GARAFFA - Monroe CT, US
Pankaj GUPTA - Scarsdale NY, US
Priyanka GUPTA - Danbury CT, US
Fei HAN - Sandy Hook CT, US
Aaron Timothy KARLAK - Beacon Falls NY, US
Dongmei LIU - Oxford CT, US
Ivo LORENZ - Brooklyn NY, US
Mouhamadou Lamine MBOW - Echichens, CH
Miguel E. MORENO-GARCIA - Sandy Hook CT, US
Joseph A. MOZDZIERZ - Mahopac NY, US
Kerry L.M. RALPH - Bethel CT, US
Abdulsalam SHAABAN - Ridgefield CT, US
Della M. WHITE - Brookfield CT, US
Helen Haixia WU - Danbury CT, US
Guangwei YANG - Cheshire CT, US

C07K 16/28

The present invention relates to new anti-PD-1 (Programmed cell death 1) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.

20210095020, Apr 1, 2021

May 11, 2020

16/871382

- Ingelheim am Rhein, DE
Ivo LORENZ - Brooklyn NY, US
Otmar SCHAFF - Vienna, AT
Melanie WURM - Vienna, AT
Jean-Francois FORTIN - Laval, CA
Scott Ronald BRODEUR - New Hope PA, US
Keith A. CANADA - Freehold NJ, US
Lukasz CHLEWICKI - Indianapolis IN, US
Walter Carroll DAVIDSON - Croton NY, US
Pankaj GUPTA - Scarsdale NY, US
Priyanka GUPTA - Danbury CT, US
Rocío K. PÉREZ - Danbury CT, US
Haiguang XIAO - Ridgefield CT, US
Danlin YANG - Philadelphia PA, US

C07K 16/28
A61K 39/395
A61K 45/06

The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.